This information should not be considered to represent advice or guidance on behalf of the U.S. Department of Health and Human Services or any agency or office thereof.

Overview of FDA Guidance on Nanotechnology Products

Context

Nanotechnology is an emerging technology used to develop innovative drug delivery systems, enhance the solubility of less water-soluble drugs, improve the bioavailability of active pharmaceutical ingredients (APIs), and enable targeted delivery of therapeutics.

Nanotechnology involves manipulating and applying materials at the nanoscale, typically ranging from 1 to 100 nanometers. At this scale, materials exhibit unique physical, chemical, and biological properties that can significantly differ from their bulk counterparts. Nanotechnology applications in pharmaceuticals include nanoparticles, liposomes, dendrimers, nanocrystals, and nanoemulsions, which can be engineered to optimize drug release, enhance stability, and reduce side effects.

The novel properties of nanomaterials have generated new regulatory approaches to assess key differences between nano-delivered and traditional delivery therapeutics including their ability to cross biological barriers, heightened reactivity, and potential for bioaccumulation. The U.S. Food and Drug Administration (FDA) has established guidelines to inform manufacturers of their expectations when evaluating nanotechnology products.

FDA's Role and Guidance

Regulatory Framework

Classifying nanotechnology products is a crucial first step in the regulatory process, as it determines the applicable regulatory pathway and specific requirements for product approval. FDA defines nanomaterials as materials with any external dimension (approximately 1 to 100 nanometers) or materials with internal or surface structures in the nanoscale.

Nanotechnology products are categorized based on their intended use, structural characteristics, and the extent to which nanotechnology alters their properties compared to conventional materials. This classification impacts the regulatory pathway, and the type of data required to support product approval, with distinctions drawn between nanomaterials and conventional materials based on their unique properties and interactions with biological systems.

Regulatory Pathways

Nanotechnology products are subject to FDA's established regulatory pathways, including the Investigational New Drug (IND) application, New Drug Application (NDA), and Biologics License Application (BLA). These pathways ensure that new drug products, including those involving nanotechnology, undergo rigorous evaluation before marketing approval.

- Investigational New Drug (IND) Application − Required before human testing, the IND application must include preclinical data demonstrating the product's safety and potential efficacy. This may include additional studies to evaluate unique properties such as biodistribution, bioaccumulation potential, and immunotoxicity for nanotechnology products.
- New Drug Application (NDA) and Biologics License Application (BLA) − These pathways require comprehensive data on the product's safety, efficacy, and quality, including detailed information on the manufacturing process and nanomaterial characterization. FDA reviews potential risks, including long-term effects and environmental impact.
- 505(b)(2) & 351(a) Applications − The 505(b)(2) pathway is available for products similar to previously approved drugs but involving new formulations or routes of administration. The 351(a) pathway is used for biological products, including those incorporating nanotechnology.

Nonclinical Studies

Objectives − Nonclinical studies are fundamental to drug development, providing critical data to assess the safety and efficacy of nanotechnology products before they advance to human clinical trials. The primary goals of these studies are to evaluate pharmacological effects, toxicological profiles, and pharmacokinetic behaviors. Unique properties of nanomaterials, such as their size, surface charge, and interactions with biological systems, necessitate tailored nonclinical studies that differ from those used for conventional drug formulations.

Toxicology Studies − Toxicology studies assess the potential adverse effects of nanotechnology products, focusing on biodistribution, accumulation, and the assessment of acute, sub-chronic, and chronic toxicity. Given the distinct toxicological profiles of nanomaterials, studies must evaluate their unique properties, such as their ability to cross biological barriers, which can lead to unexpected tissue accumulation and potential toxicity.

Pharmacokinetics and Biodistribution − Pharmacokinetic (PK) and biodistribution studies are critical for understanding how nanotechnology products are absorbed, distributed, metabolized, and excreted (ADME). The unique properties of nanomaterials, including their small size and surface characteristics, can significantly impact their pharmacokinetic profiles, requiring comprehensive study designs to ensure safety and efficacy.

Immunotoxicity and Genotoxicity − Nanomaterials have the potential to interact with the immune system differently than traditional drug formulations, leading to increased risk of immunotoxicity. Studies must evaluate the potential for chronic immune activation and the risk of immunogenicity, especially for long-term use products. Genotoxicity studies assess whether nanomaterials can cause genetic damage, which could lead to mutations, cancer, or other genetic disorders, necessitating a combination of *in vitro* and *in vivo* assays.

Preclinical and Clinical Studies

Preclinical studies serve as a bridge between nonclinical findings and human clinical trials, often involving additional testing in animal models to validate the relevance of nonclinical results to human conditions. These studies provide further evidence of safety and efficacy, particularly when scaling from small-scale laboratory experiments to larger-scale clinical applications.

Clinical Studies

Phase I clinical trials represent the first human studies of nanotechnology products, focusing on safety, tolerability, and pharmacokinetics. Phase II and III trials evaluate the efficacy and monitor long-term safety, including post-marketing surveillance to detect adverse events that may emerge after widespread product use. Special considerations include unique safety signals associated with nanomaterials, biomarker development, personalized medicine approaches, and the inclusion of pediatric and geriatric populations.

Chemistry, Manufacturing and Controls (CMC)

- **Characterization of Nanomaterials** − Characterizing nanomaterials includes determining their physical and chemical properties, such as size, shape, surface charge, and chemical composition, as these characteristics significantly impact behavior in biological systems.
- **Manufacturing Processes and Quality Control** − Manufacturing nanotechnology products pose challenges related to scaling up while maintaining quality. Rigorous process validation and optimization are necessary to ensure consistency and performance. Robust quality control measures are critical to ensuring each batch meets predefined acceptance and stability specifications (based on the characterization studies mentioned above).
- **Quality by Design (QbD) for Nanotechnology** − FDA encourages the application QbD principles, emphasizing a systematic approach to pharmaceutical development that focuses on understanding the relationship between formulation, process, and product quality. This helps ensure consistent production of high-quality nanotechnology products., emphasizing a systematic approach to pharmaceutical development that focuses on understanding the relationship between formulation, process, and product

quality. This helps ensure consistent production of high-quality nanotechnology products.

Summary

Nanotechnology offers transformative opportunities in pharmaceuticals, enabling innovative drug delivery systems and improving patient outcomes. However, the unique properties of nanomaterials present new regulatory challenges. FDA has a comprehensive framework for regulating nanotechnology products, covering all aspects, from nonclinical studies to clinical trials, CMC considerations, and safety assessments. Continuous research and collaboration among industry, academia, and regulatory agencies is essential for advancing the field and ensuring the safe and effective development of nanotechnology products.

Resources

FDA: FDA's Approach to Regulation of Nanotechnology Products
FDA: Nanotechnology Guidance Documents
FDA: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology
FDA: Drug Products Including Biological Products that Contain Nanomaterials
FDA: Nonclinical Perspective on Development of Drug Products Containing Nanomaterials
FDA: Developing Drug Products Containing Nanomaterials: CDER CMC Perspective
FDA: Guidance for Industry: Safety of Nanomaterials in Cosmetic Products
Article: A Comprehensive QBD Strategy for Nanotherapeutics Development: A Review